The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics
- 9 Downloads
Purpose of review
The emerging complexity of cardiac toxicity caused by cancer therapies has created demand for more advanced non-invasive methods to better evaluate cardiac structure, function, and myocardial tissue characteristics. Cardiac magnetic resonance imaging meets these needs without exposure to ionizing radiation, and with superior spatial resolution.
Special applications of cardiac magnetic resonance (CMR) to assess for cancer therapy–induced cardiac toxicity include the detection of subclinical LV dysfunction through novel methods of measuring myocardial strain, detection of microcirculatory dysfunction, identification of LV and LA fibrosis, and more sensitive detection of inflammation caused by immune checkpoint inhibitors.
CMR plays a significant role in the non-invasive workup of cardiac toxicity from cancer therapies, with recent advancements in the field that have opened avenues for further research and development.
KeywordsCardiac magnetic resonance imaging Cancer therapeutics–related cardiac dysfunction Anthracyclines Late gadolinium enhancement Myocardial perfusion
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.CrossRefGoogle Scholar
- 6.Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84. https://doi.org/10.1016/j.jacc.2012.09.035.PubMedCrossRefGoogle Scholar
- 7.Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28:3429–36.PubMedCrossRefGoogle Scholar
- 8.Akhavan Malayeri A, Johnson WC, Macedo R, et al. Cardiac cine MRI: quantification of the relationship between fast gradient echo and steady-state free precession for determination of myocardial mass and volumes. J Magn Reson Imaging. 2008;28(1):60–6. https://doi.org/10.1002/jmri.21405.CrossRefGoogle Scholar
- 13.Kwan JM, Arbune A, Henry M, et al. Cardiac magnetic resonance imaging feature tracking strain as a sensitive marker of cardiotoxicity in breast cancer patients compared with left ventricular ejection fraction. American College of Cardiology Scientific Sessions, New Orleans, LA. 2019. Accepted abstract.CrossRefGoogle Scholar
- 14.Jolly MP, Jordan JH, Melendez GC, McNeal GR, D’Agostino RB Jr, Hundley WG. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson. 2017;19:59.PubMedPubMedCentralCrossRefGoogle Scholar
- 15.Giusca S, Korosoglou G, Zieschang V, et al. Reproducibility study on myocardial strain assessment using fast-SENC cardiac magnetic resonance imaging. Sci Rep. 2018;8(1).Google Scholar
- 16.Barthur A, Brezden-Masley C, Connelly K, et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19:44. https://doi.org/10.1186/s12968-017-0356-4.PubMedPubMedCentralCrossRefGoogle Scholar
- 19.Soufer A, Peters DC, Henry ML, et al. Advanced imaging of the left atrium with cardiac magnetic resonance: a review of current and emerging methods and clinical applications. Curr Radiol Rep. 2018;6:44 https://doi.org/10.1007/s40134-018-0303-7.
- 20.Wandelet LK, Kowallick JT, Schuster A, Wachter R, Stumpfig T, et al. Quantification of left atrial volume and phasic function using cardiovascular magnetic resonance imaging-comparison of biplane area-length method and Simpson’s method. Int J Cardiovasc Imaging. 2017;33(11):1761–9.CrossRefGoogle Scholar
- 23.Hu C, Boutagy N, Feher A, et al. Multi-parametric mri evaluation of doxorubicin-induced cardiotoxicity in a canine model. Society Cardiac Mag Resonance Scientific Sessions, 2019, abstract.Google Scholar
- 29.Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II–positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57:2263–70.PubMedCrossRefGoogle Scholar
- 31.Drafts BC, Twomley KM, D’Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–85.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.•Muehlberg F, Funk S, Zange L, et al. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail. 2018;5(4):620–9 This recent study shows that early decrease in left ventricular native T1 times may predict future decline in LV function after exposure to anthracyclines.PubMedPubMedCentralCrossRefGoogle Scholar
- 35.•Ferreira de Souza T, Quinaglia ACST, Osorio Costa F, et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 2018;11(8):1045–55 This article suggests that elevated ECV may be related to cardiomyocyte atrophy, the degree of which appeared to correlate with myocardial injury as measured by troponin T values.PubMedGoogle Scholar
- 37.Chubb H, Aziz S, Karim R, Sohns C, Razeghi O, et al. Optimization of late gadolinium enhancement cardiovascular magnetic resonance imaging of post-ablation atrial scar: a cross-over study. J Cardiovasc Magn Reson. 2018;20:30. https://doi.org/10.1186/s12968-018-0449-8.PubMedPubMedCentralCrossRefGoogle Scholar
- 38.Harrison A, Damal K, Burgon NS, Haslam MM, Glenn M, et al. Left atrial late gadolinium enhancement following external beam radiation for lymphoma: a potential model for exploring radiation-related heart disease. J Cardiovasc Magn Reson. 2012;187.Google Scholar
- 42.Hu C, Sinusas AJ, Huber S, Thorn S, Stacy MR, et al. T1-refBlochi: high resolution 3D post-contrast T1 myocardial mapping based on a single 3D late gadolinium enhancement volume, Bloch equations, and a reference T1. J Cardiovasc Magn Reson. 2017;19:63. https://doi.org/10.1186/s12968-017-0375-1.PubMedPubMedCentralCrossRefGoogle Scholar
- 45.•Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in non-ischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–76 This article provides updates to the Lake Louise Criteria to diagnose myocarditis with CMR and includes recommendations to implement native T2 mapping in the evaluation of myocarditis.Google Scholar
- 50.Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol. 2013;62:1639–53.PubMedCrossRefGoogle Scholar
- 52.Greenwood JP, Meredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379(9814):453–60. https://doi.org/10.1016/S0140-6736(11)61335-4.PubMedPubMedCentralCrossRefGoogle Scholar
- 54.Schwitter J, Wacker CM, Wilke N, et al. MR-IMPACT II: magnetic resonance imaging for myocardial perfusion assessment in coronary artery disease trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. Eur Heart J. 2013;34(10):775–81.PubMedCrossRefGoogle Scholar
- 57.Kotecha T, Martinez-Naharro A, Boldrini M, et al. Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: validation against invasive coronary physiology. JACC Cardiovasc Imaging. 2019. https://doi.org/10.1016/j.jcmg.2018.12.022.
- 58.•Liu A, Wijesurendra RS, Liu JM, et al. Gadolinium free Cardiac MR Stress T1-Mapping to Distinguish Epicardial from Microvascular Coronary Artery Disease. J Am Coll Cardiol. 2018;71(9):957–68 This group provides a stress CMR protocol without the use of GBCA, by using quantitative T1 mapping pre- and post-adenosine to quantify changes in MBF. This may be useful in the characterization of microcirculatory dysfunction in patients exposed to potentially cardiotoxic cancer therapies.Google Scholar
- 60.Indorkar R, Kwong RY, Romano S, et al. Global coronary flow reserve measured during stress cardiac magnetic resonance imaging is an independent predictor of adverse cardiovascular events. JACC Cardiovasc Imaging. 2018. https://doi.org/10.1016/j.jcmg.2018.08.018.
- 61.Nguyen V, Baldassarre L. Stress cardiovascular magnetic resonance for evaluation of antineoplastic associated cardiotoxicity in a real-world cohort of breast cancer patients. Society of Cardiovascular Magnetic Resonance Scientific Sessions, 2018, abstract.Google Scholar
- 62.Park C, Tjomas AL, Hundley WG, et al. Adenosine stress response with native T1 mapping is associated with contrasted first pass perfusion cardiac magnetic resonance imaging in cancer survivors treated with anthracyclines: measuring coronary microvascular dysfunction in cardio-oncology without contrast. ACC 2019 Scientific Sessions. 2019;73(9 Supplement 1). https://doi.org/10.1016/S0735-1097(19)32184-9 CrossRefGoogle Scholar
- 76.Soufer, A, Higgins A, Baldassarre, L. Quantitative analysis of T2 imaging may identify global edema in patients referred for immune checkpoint inhibitor cardiomyopathy. 2019 Society of Cardiovascular Magnetic Resonance Scientific Sessions, abstract.Google Scholar
- 77.Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA, et al. Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. yty149, https://doi.org/10.1093/ehjcr/yty149
- 78.Higgins A, Soufer A, Nguyen V, et al. Cardiac magnetic resonance imaging aids in diagnosis of suspected immune checkpoint inhibitor mediated cardiotoxicity. Global conference of Cardio Oncology Scientific Sessions, 2018, abstract.Google Scholar